Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Orthocell Ltd (ASX:OCC, OTC:ORHHF). The company has raised A$17 million to accelerate the US launch of its Remplir™ collagen wrap for peripheral nerve repair. Funds will also support global expansion for both Remplir™ and Striate+™, a resorbable collagen membrane for dental bone and tissue regeneration. Institutional investors, high net worth individuals and family offices contributed to the raise, resulting in the issuance of up to 28,333,333 million new shares at A$0.60 each. With a strengthened cash position of approximately A$35 million and no debt, Orthocell is positioned to scale up manufacturing, improve automation and grow its market reach across the US, Singapore, Southeast Asia, Canada and the EU/UK. Regulatory processes are advancing with the company on track to submit its US 510(K) application for Remplir this quarter. FDA approval is anticipated to follow, enabling rapid market entry. The capital raise reinforces Orthocell’s growth trajectory, allowing for faster expansion into the US market and acceleration of its product pipeline. #ProactiveInvestors #Orthocell #ASX #Remplir #StriatePlus #MedicalDevices #CapitalRaise #USLaunch #FDAApproval #PeripheralNerveRepair #DentalRegeneration #RegenerativeMedicine #CollagenWrap #MarketExpansion #ASX #MedicalInnovation #HealthTech #GlobalCommercialisation #InvestmentNews #MedTech #OrthocellGrowth #Healthcare